Efficacy and safety of Buxus sempervirens L. preparations (SPV(30)) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial.

The objective of the present study was to compare the efficacy and safety of two doses of SPV(30) in HIV asymptomatic patients. The study was designed as a randomized double-blind multicentre trial of two doses of SPV(30) (990 mg/d and 1980 mg/d) versus placebo. 145 previously untreated subjects with asymptomatic HIV infection (CDC group IV) and CD4 cell counts between 250 and 500 × 10(6)/1 were recruited. There was a statistically significant difference in therapeutic failures between groups in favor of SPV(30) 990 mg including decreases of CD4 cell count < 200 × 10(6)/1 and/or number of clinical aggravations (progression to AIDS or AIDS related complex). The treatment groups differed statistically in the rate of disease progression also in favor of SPV(30) 990 mg/d. Fewer patients receiving SPV(30) 990 mg/d had at the end an increase of viral load greater than 0.5 log (P = 0.029). No severe side-effects were reported in the 3 groups. From these results we conclude that SPV(30) 990 mg/d has beneficial effects in HIV asymptomatic patients and appears to delay the progression of HIV disease.

[1]  R. Hocquemiller,et al.  Spirofornabuxine, a Novel Type of Buxus Alkaloid. , 1997 .

[2]  E L Kaplan.  NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION , 1958 .

[3]  H. B. Mann,et al.  On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other , 1947 .

[4]  G. Donelli,et al.  N‐Acetylcysteine inhibits apoptosis and decreases viral particles in HIV‐chronically infected U937 cells , 1993, FEBS letters.

[5]  Z. Votický,et al.  Alkaloids of buxus sempervirens L. - VI - structure of buxpsiine. , 1966 .

[6]  J. Sninsky,et al.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.

[7]  Robert Schooley,et al.  CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.

[8]  M. Choudhary,et al.  Chemical constituents of Buxus sempervirens , 1988 .

[9]  W. Blattner,et al.  Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. , 1989, Journal of acquired immune deficiency syndromes.

[10]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[11]  A. Aumelas,et al.  Four steroidal alkaloids from the leaves of Buxus sempervirens. , 2000, Phytochemistry.

[12]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[13]  J M Taylor,et al.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. , 1990, The New England journal of medicine.

[14]  E. Lissi,et al.  ANTIOXIDANT ACTIVITIES OF LIGNANS AND FLAVONOIDS , 1990 .

[15]  R. Larson.  The antioxidants of higher plants , 1988 .

[16]  P. Volberding.  HIV quantification: clinical applications , 1996, The Lancet.

[17]  C. Verhofstede,et al.  Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV‐1 infection: correlation with virological and immunological markers of disease , 1994, AIDS.

[18]  D.,et al.  Regression Models and Life-Tables , 2022 .

[19]  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.

[20]  M. Choudhary,et al.  Chemical Constituents of Buxus sempervirens. , 1988, Planta medica.